Lou de Leij

2.3k total citations
51 papers, 1.9k citations indexed

About

Lou de Leij is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Lou de Leij has authored 51 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 19 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Oncology. Recurrent topics in Lou de Leij's work include Monoclonal and Polyclonal Antibodies Research (16 papers), Glycosylation and Glycoproteins Research (12 papers) and Lung Cancer Research Studies (5 papers). Lou de Leij is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (16 papers), Glycosylation and Glycoproteins Research (12 papers) and Lung Cancer Research Studies (5 papers). Lou de Leij collaborates with scholars based in Netherlands, United States and Germany. Lou de Leij's co-authors include Wijnand Helfrich, T H Thé, Bart‐Jan Kroesen, Edwin Bremer, Grietje Molema, Jeff W. M. Bulte, Sandrine Audouy, R. L. Kamman, Dick Hoekstra and K.G. Go and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Molecular and Cellular Biology.

In The Last Decade

Lou de Leij

51 papers receiving 1.9k citations

Peers

Countries citing papers authored by Lou de Leij

Since Specialization

Citations

This map shows the geographic impact of Lou de Leij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lou de Leij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lou de Leij more than expected).

Fields of papers citing papers by Lou de Leij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lou de Leij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lou de Leij. The network helps show where Lou de Leij may publish in the future.

Co-authorship network of co-authors of Lou de Leij

This figure shows the co-authorship network connecting the top 25 collaborators of Lou de Leij. A scholar is included among the top collaborators of Lou de Leij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lou de Leij. Lou de Leij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeted induction of apoptosis for cancer therapy: current progress and prospects 2006 ·Trends in Molecular Medicine ·Edwin Bremer, (unknown), (unknown), Lou de Leij, Wijnand Helfrich	101
2	Porcine Fetal Ventral Mesencephalic Cells are Targets for Primed Xenoreactive Human T Cells 2006 ·Cell Transplantation ·(unknown), Aalzen de Haan, (unknown), Bernardina T.F. van der Gun, Henk van Dijk, Jan Rozing, Lou de Leij, Michiel J. Staal	5
3	Individual Human Serum Differs in the Amount of Antibodies with Affinity for Pig Fetal Ventral Mesencephalic Cells and the Ability to Lyse These Cells by Complement Activation 2004 ·Cell Transplantation ·(unknown), Aalzen de Haan, (unknown), Bernardina T.F. van der Gun, Henk van Dijk, Jan Rozing, Lou de Leij, Michiel J. Staal	5
4	Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 2003 ·International Journal of Cancer ·Edwin Bremer, Jos M.A. Kuijlen, Douwe F. Samplonius, Henning Walczak, Lou de Leij, Wijnand Helfrich	75
5	The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers 2001 ·European Journal of Clinical Pharmacology ·Wim J. Tamminga, J. Wemer, B. Oosterhuis, (unknown), Lou de Leij, J. H. G. Jonkman	81
6	A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions 2000 ·Journal of Immunological Methods ·Wijnand Helfrich, Hidde J. Haisma, (unknown), Thomas Luther, V J J Bom, Jantine L. Westra, (unknown), (unknown), Grietje Molema, Lou de Leij	21
7	Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas 1998 ·International Journal of Cancer ·Wijnand Helfrich, (unknown), Rob C. Roovers, Lidia Westers, Grietje Molema, Hennie R. Hoogenboom, Lou de Leij	40
8	Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas 1998 ·International Journal of Cancer ·Wijnand Helfrich, (unknown), Rob C. Roovers, Lidia Westers, Grietje Molema, Hennie R. Hoogenboom, Lou de Leij	2
9	Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1 1997 ·Cancer Immunology Immunotherapy ·Bart‐Jan Kroesen, (unknown), D.Th. Sleijfer, Grietje Molema, Elisabeth G.E. de Vries, Harry J.M. Groen, Wijnand Helfrich, T H Thé, Nanno H. Mulder, Lou de Leij	27
10	Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb 1994 ·Cancer Immunology Immunotherapy ·Richard A. J. Janssen, (unknown), (unknown), Lou de Leij	6
11	The immunobiological effects of interleukin-2 in vivo 1994 ·Cancer Immunology Immunotherapy ·Richard A. J. Janssen, Nanno H. Mulder, (unknown), Lou de Leij	38
12	Detection of a putative 30-kDa ligand of the cluster-2 antigen 1994 ·International Journal of Cancer ·Wijnand Helfrich, Michel van Geel, (unknown), Lou de Leij	10
13	Epitope mapping of SCLC-cluster-2 MAbs and generation of antibodies directed against new EGP-2 epitopes 1994 ·International Journal of Cancer ·Wijnand Helfrich, (unknown), (unknown), Lou de Leij	21
14	Magnetite as a Potent Contrast-Enhancing Agent in Magnetic Resonance Imaging to Visualize Blood-Brain Barrier Disruption 1993 ·PubMed ·Jeff W. M. Bulte, (unknown), R. L. Kamman, (unknown), T H Thé, Lou de Leij, K. G. Go	10
15	Refinement of an indirect immunotoxin assay of monoclonal antibodies recognising the human small cell lung cancer cluster 2 antigen 1993 ·British Journal of Cancer ·(unknown), Lou de Leij, (unknown)	5
16	Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma 1992 ·British Journal of Cancer ·René A. J. Janssen, (unknown), (unknown), (unknown), (unknown), Lou de Leij	5
17	Specific MR imaging of human lymphocytes by monoclonal antibody‐guided dextran‐magnetite particles 1992 ·Magnetic Resonance in Medicine ·Jeff W. M. Bulte, (unknown), R. L. Kamman, Richard L. Magin, Andrew Webb, Richard W. Briggs, K.G. Go, Caesar E. Hulstaert, Stefan Miltenyi, T H Thé, Lou de Leij	112
18	Dextran‐magnetite particles: Contrast‐enhanced MRI of blood–brain barrier disruption in a rat model 1992 ·Magnetic Resonance in Medicine ·Jeff W. M. Bulte, (unknown), R. L. Kamman, K. G. Go, (unknown), Bert Blaauw, (unknown), (unknown), Lou de Leij	36
19	Direct visualisation and quantification of cellular cytotoxicity using two colour fluorescence 1992 ·Journal of Immunological Methods ·Bart‐Jan Kroesen, G Mesander, (unknown), T H Thé, Lou de Leij	60
20	Characteristics of a multicopy gene family predominantly consisting of processed pseudogenes 1989 ·Nucleic Acids Research ·Ans M.W. van den Ouweland, Hans L. P. van Duijnhoven, Klaus A. Deichmann, J.J.M. van Groningen, Lou de Leij, Wim J.M. Van de Ven	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact